Just a moment, the page is loading...

Myovant Sciences Investigator Initiated Studies (IIS)

We are dedicated to improving the quality of human life and advancing medical sciences. As part of this commitment, we recognize the valuable role that our support of investigator-initiated studies (IIS) plays in fulfilling this mission. An investigator-initiated study is a research effort where the sponsor of work is an investigator, healthcare institution, or some form of external medical network and is seeking our support to conduct the research. This support can be in the form of product, funding, or a combination of both.

We will only support IIS that have legitimate scientific or medical purpose consistent with Myovant's scientific and medical objectives. The decision to support a study proposal is based on the importance of the research objectives to medical science or patient care, the scientific rationale for the proposed methodology, and the ability of the study sponsor to deliver a high-quality ethical study.

Therapeutic Areas of Interest

We currently welcome unsolicited research proposals from qualified sponsors with promising ideas in the following therapeutic areas:

  • Men's Health
    • Prostate Cancer
      • Use of relugolix in combination with other prostate cancer systemic or localized therapies (e.g., hormonal/chemotherapy drug combinations, novel targeted agents, radiotherapy, etc.)
      • Longer-term efficacy and safety outcomes with relugolix (18+ months of planned ADT)
      • Use of relugolix as intermittent androgen deprivation in appropriate settings
      • Relugolix impact on Quality of Life/Patient Reported Outcomes, medication adherence, and patient preferences
      • Use of relugolix in different patient subpopulations at high risk for health care disparities

If you have any questions, please reach out to your Regional Medical Advisor (RMA). For assistance in identifying the RMA for your territory or for general inquiries, please email us at IIS@Myovant.com.



Apply here